6-fluoroheptanol | 178622-30-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 6-fluoroheptanol
• 英文别名: 6-Fluoro-1-heptanol；6-Fluoroheptan-1-ol
• CAS: 178622-30-5
• 化学式: C₇H₁₅FO
• 分子量: 134.194
• InChiKey: DKDFZJLHHLIVFV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  9
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-fluoroheptanol 在 N-溴代丁二酰亚胺(NBS) 、 三苯基膦 作用下， 以 苯 为溶剂， 反应 5.5h， 以93.6%的产率得到1-bromo-6-fluoroheptane
  参考文献：
  名称：

  Progress toward the Development of a Safe and Effective Agent for Treating Reentrant Cardiac Arrhythmias:  Synthesis and Evaluation of Ibutilide Analogues with Enhanced Metabolic Stability and Diminished Proarrhythmic Potential

  摘要：

  A series of ibutilide analogues with fluorine substituents on the heptyl side chain was prepared and evaluated for class III antiarrhythmic activity, metabolic stability, and proarrhythmic potential. It was found that fluorine substituents stabilized the side chain to metabolic oxidation. Many of the compounds also retained the ability to increase the refractoriness of cardiac tissue at both slow and fast pacing rates. The potential for producing polymorphic ventricular tachycardia in the rabbit model was dependent on the chirality of the benzylic carbon. The S-enantiomers generally had less proarrhythmic activity than the corresponding racemates. One compound from this series (45E, trecetilide fumarate) had excellent antiarrhythmic activity and metabolic stability and was devoid of proarrhythmic activity in the rabbit model. It was chosen for further development.

  DOI：

  10.1021/jm0004289
• 作为产物：
  描述：

  ethyl 6-hydroxyheptanoate 在 lithium aluminium tetrahydride 、 4,4'-二氨基二苯乙烯-2,2'-二磺酸 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 反应 4.58h， 生成 6-fluoroheptanol
  参考文献：
  名称：

  Progress toward the Development of a Safe and Effective Agent for Treating Reentrant Cardiac Arrhythmias:  Synthesis and Evaluation of Ibutilide Analogues with Enhanced Metabolic Stability and Diminished Proarrhythmic Potential

  摘要：

  A series of ibutilide analogues with fluorine substituents on the heptyl side chain was prepared and evaluated for class III antiarrhythmic activity, metabolic stability, and proarrhythmic potential. It was found that fluorine substituents stabilized the side chain to metabolic oxidation. Many of the compounds also retained the ability to increase the refractoriness of cardiac tissue at both slow and fast pacing rates. The potential for producing polymorphic ventricular tachycardia in the rabbit model was dependent on the chirality of the benzylic carbon. The S-enantiomers generally had less proarrhythmic activity than the corresponding racemates. One compound from this series (45E, trecetilide fumarate) had excellent antiarrhythmic activity and metabolic stability and was devoid of proarrhythmic activity in the rabbit model. It was chosen for further development.

  DOI：

  10.1021/jm0004289

文献信息

• Antiarrhythmic (S)-enantiomers of methanesulfonamides
  申请人：Pharmacia & Upjohn Company

  公开号：US05874475A1

  公开（公告）日：1999-02-23

  Compounds of formula (I) and pharmacologically acceptable salts thereof wherein: n is 1 to 3, R is an alkyl, R.sub.1 is hydrogen or alkyl, R.sub.2 is alkyl, R.sub.3 is an alkyl; b) alkyl substituted with an aryl, heteroaryl or cycloalkyl; c) alkyl substituted with one to eight fluorine atoms; d) cycloalkyl; e) alkenyl; f) alkyl substituted with one to three hydroxy, acyloxy or alkoxy substituents, and where the sum of carbons in R.sub.2 and R.sub.3 is greater than five br where R.sub.2 and R.sub.3 with the nitrogen atom form a saturated heterocyclic group having one nitrogen and form 4-8 carbon atoms or a 4-substituted piperazine group in which the 4-substituent can be alkyl, aryl, benzyl, or heteroaryl, and X is hydrogen, hydroxy, alkoxy, alkyl, carbon trifluoride or a halogen, or compounds of formula (I') and pharmacologically acceptable salts thereof wherein: n is 1 to 3, R is an alkyl, R.sub.1 is hydrogen or alkyl, R.sub.2 is an alkyl, R.sub.3 is an alkyl substituted with an aryl, heteroaryl or cycloalkyl, or an alkyl substituted with one to eight fluorine atoms, one to three hydroxy, acyloxy or alkoxy substituents, and where the sum of carbons in R.sub.2 and R.sub.3 is greater than five; X is hydrogen, hydroxy, alkoxy, alkyl, carbon trifluoride or a halogen, useful as class III antiarrhythmic agents.

  式（I）的化合物及其药理学上可接受的盐，其中：n为1至3，R为烷基，R.sub.1为氢或烷基，R.sub.2为烷基，R.sub.3为烷基；b）烷基与芳基，杂环烷基或环烷基取代；c）烷基取代一个至八个氟原子；d）环烷基；e）烯烃基；f）烷基取代一个至三个羟基，乙酰氧基或烷氧基取代基，其中R.sub.2和R.sub.3中碳的总和大于五br，其中R.sub.2和R.sub.3与氮原子形成一个饱和的杂环基，含有一个氮原子并形成4-8个碳原子，或者形成一个4-取代哌嗪基团，其中4-取代基可以是烷基，芳基，苄基或杂环基，X为氢，羟基，烷氧基，烷基，三氟甲基或卤素，或者式（I'）的化合物及其药理学上可接受的盐，其中：n为1至3，R为烷基，R.sub.1为氢或烷基，R.sub.2为烷基，R.sub.3为烷基，取代一个芳基，杂环烷基或环烷基，或者取代一个至八个氟原子，一个至三个羟基，乙酰氧基或烷氧基取代基，其中R.sub.2和R.sub.3中碳的总和大于五；X为氢，羟基，烷氧基，烷基，三氟甲基或卤素，作为III类抗心律失常药物。
• [EN] ANTIARRHYTHMIC (S)-ENANTIOMERS OF METHANESULFONAMIDES<br/>[FR] ENANTIOMERES (S) DE METHANE-SULFONAMIDES ANTIARYTHMIQUES
  申请人：PHARMACIA & UPJOHN COMPANY

  公开号：WO1996021643A1

  公开（公告）日：1996-07-18

  (EN) (S)-Enantiomeric methanesulfonamides are structurally depicted by formula (I) or its pharmacologically acceptable salts where R3 is a C1-9 alkyl substituted with one fluorine atom. These compounds are useful as Class III antiarrhythmic agents without the undesirable side effect of polymorphic ventricular tachycardia (PVT) and are stable against rapid metabolism. Use of the compounds of formula (I) in the preparation of compositions for treating cardiac arrhythmias are also described.(FR) Méthane-sulfonamides énantiomères (S) décrits, au point de vue de la structure, par la formule (I) ou les sels pharmacologiquement acceptables du composé décrit par celle-ci, où R3 est un alkyle en C1-C9 substitué avec un atome de fluor. Ces composés sont utiles en tant qu'agents antiarythmiques de classe III n'ayant pas l'effet secondaire indésirable qu'est la tachycardie ventriculaire polymorphe et sont stables vis-à-vis d'un métabolisme rapide. L'invention décrit également l'utilisation desdits composés de formule (I) dans des préparations servant au traitement d'arythmies cardiaques.

  （EN）（S）-对映甲磺酰胺的结构式如公式（I）或其药学上可接受的盐所示，其中R3是一个C1-9烷基，被一个氟原子取代。这些化合物可用作III类抗心律失常药物，不会产生多形性室性心动过速（PVT）的不良副作用，并且稳定不易被迅速代谢。本发明还描述了将公式（I）化合物用于制备治疗心律失常的组合物的用途。 （FR）（S）-对映甲磺酰胺的结构式如公式（I）或其药学上可接受的盐所示，其中R3是一个C1-9烷基，被一个氟原子取代。这些化合物可用作III类抗心律失常药物，不会产生多形性室性心动过速（PVT）的不良副作用，并且稳定不易被迅速代谢。本发明还描述了将公式（I）化合物用于制备治疗心律失常的组合物的用途。
• Heteroaryloxy nitrogenous saturated heterocyclic derivative
  申请人：Ohtake Norikazu

  公开号：US20060178375A1

  公开（公告）日：2006-08-10

  Compound of the formula: (I) [wherein each of X 1 , X 2 , and X 3 independently represents N or CH, W represents the formula (II):(II) or the formula (III):(III) and Y represents a group of the formula (IV):(IV)], or a pharmacologically acceptable salt thereof. This compound exhibits histamine receptor H3 antagonist or inverse agonist activity and is useful of the treatment and/or prevention of obesity, diabetes, hormonal secretion abnormality, sleep, disorder, etc.

  该化合物的化学式为（I），其中X1、X2和X3分别独立地代表N或CH，W代表式（II）：（II）或式（III）：（III），Y代表式（IV）的基团：（IV），或其药学上可接受的盐。该化合物表现出组胺H3受体拮抗剂或倒向激动剂活性，可用于治疗和/或预防肥胖症、糖尿病、激素分泌异常、睡眠障碍等疾病。
• HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE
  申请人：Ohtake Norikazu

  公开号：US20100210637A1

  公开（公告）日：2010-08-19

  Provided are compounds of a formula (I) and their pharmaceutically-acceptable salts: wherein X1, X2 and X3 each independently represent N or CH; W represents the following formula (II): or the following formula (III): Y represents a group of a formula (IV): The compounds have a histamine-H3 receptor antagonistic or inverse-agonistic activity and are useful for remedy and/or prevention of obesity, diabetes, hormone secretion disorders, sleep disorders, etc.

  提供的是公式（I）的化合物及其药学上可接受的盐： 其中，X1、X2和X3各自独立表示N或CH；W表示以下公式（II）： 或以下公式（III）： Y表示以下公式（IV）的基团： 这些化合物具有组胺H3受体拮抗或反拮抗活性，可用于治疗和/或预防肥胖症、糖尿病、激素分泌障碍、睡眠障碍等。
• 4-(4-METHANESULFONAMIDOPHENYL)BUTYLAMINE DERIVATIVES WITH ANTIARRHYTHMIC ACTIVITY
  申请人：PHARMACIA & UPJOHN COMPANY

  公开号：EP0781273A1

  公开（公告）日：1997-07-02